Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 3:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 62 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Leukapheresis Clear all
Terminated No phase listed Observational Accepts healthy volunteers

Stem Cell Collection for Adult Volunteers

NCT00033774
View directory record Official record
Conditions
Sickle Cell
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Sep 2, 2026, 3:54 PM EDT
Completed Phase 1 Interventional

Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab

NCT01416974
View directory record Official record
Conditions
Leukemia
Interventions
cyclophosphamide, modified T cells
Drug · Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Sep 2, 2026, 3:54 PM EDT
Completed Phase 2 Interventional Results available

Evaluate Rituximab in Obtaining PCR (Polymerase Chain Reaction) Negative Leukapheresis Product in Patients With Relapsed Follicular Lymphoma

NCT00856245
View directory record Official record
Conditions
Non-Hodgkins Lymphoma
Interventions
Rituximab
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 2, 2026, 3:54 PM EDT
Completed Phase 2 Interventional

Mobilization of Stem Cells With G-CSF for Collection From Patients With Diamond-Blackfan Anemia

NCT00011505
View directory record Official record
Conditions
Diamond Blackfan Anemia
Interventions
G-CSF, Leukapheresis
Drug · Procedure
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 2, 2026, 3:54 PM EDT
Terminated No phase listed Observational

Collection of Blood, Bone Marrow, Leukapheresis, and Tissue Biopsy Samples From Patients and Their Family Members for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases Laboratory Research Studies

NCT01200823
View directory record Official record
Conditions
Idopathic Inflammatory/Autoimmune Syndromes
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 19, 2018 · Synced Sep 2, 2026, 3:54 PM EDT
Completed No phase listed Observational

Prospective Tissue Collection Research Protocol

NCT03517917
View directory record Official record
Conditions
Solid Tumor
Interventions
Tumour tissue collection
Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
3
States / cities
New York, New York • Durham, North Carolina • Georgetown, Washington
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Sep 2, 2026, 3:54 PM EDT
Terminated No phase listed Observational

Apheresis to Obtain Plasma or White Blood Cells for Laboratory Studies

NCT00001349
View directory record Official record
Conditions
Leukopheresis, Plasmapheresis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Sep 2, 2026, 3:54 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Mobilization and Handling of Stem Cells for Transplant From Healthy Volunteers With Sickle Cell Trait

NCT00005782
View directory record Official record
Conditions
Sickle Cell Trait
Interventions
Granulocyte colony-stimulating factor, Leukapheresis
Drug · Procedure
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 2, 2026, 3:54 PM EDT
Active, not recruiting Phase 2 Interventional

Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors

NCT03967223
View directory record Official record
Conditions
Neoplasms
Interventions
Letetresgene autoleucel (lete-cel, GSK3377794), Fludarabine, Cyclophosphamide
Drug
Lead sponsor
USWM CT, LLC
Industry
Eligibility
10 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
24
States / cities
Duarte, California • Stanford, California • Denver, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 2, 2026, 3:54 PM EDT
Recruiting No phase listed Observational

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

NCT04981119
View directory record Official record
Conditions
Solid Tumor, Adult, Colorectal Cancer, Non Small Cell Lung Cancer, Pancreatic Cancer, CRC, NSCLC, Pancreas Cancer, Mesothelioma, Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Mesothelioma, Malignant, Mesothelioma; Lung, Cancer, Triple Negative Breast Cancer (TNBC), Renal Cell Carcinoma (Kidney Cancer), Head and Neck Squamous Cell Carcinoma HNSCC
Interventions
Apheresis, Next Generation Sequencing (NGS), Long Range NGS HLA typing
Other · Diagnostic Test
Lead sponsor
A2 Biotherapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
16
States / cities
Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 2, 2026, 3:54 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Apheresis and Specimen Collection Procedures to Obtain Plasma, Peripheral Blood Mononuclear Cells (PBMCs) and Other Specimens for Research Studies

NCT00067054
View directory record Official record
Conditions
Sample Collection
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years and older
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2003
U.S. locations
2
States / cities
Bethesda, Maryland • Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 2, 2026, 3:54 PM EDT
Active, not recruiting Phase 1 Interventional

Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19

NCT01044069
View directory record Official record
Conditions
Leukemia, Acute Lymphoblastic Leukemia
Interventions
gene-modified T cells targeted
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Sep 2, 2026, 3:54 PM EDT
Terminated Not applicable Interventional Results available

Procurement of Leukapheresis Products From End Stage Liver Disease (ESLD) Patients for Immunological Studies

NCT02447926
View directory record Official record
Conditions
End Stage Liver Disease
Interventions
Leukapheresis
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 89 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Sep 2, 2026, 3:54 PM EDT
Recruiting No phase listed Observational

Leukapheresis to Obtain Plasma or Lymphocytes for Studies of HIV-infected Patients, Including Long-term Non-progressors

NCT00029445
View directory record Official record
Conditions
HIV
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 100 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 2, 2026, 3:54 PM EDT
Terminated Phase 1 Interventional Results available

Study of GSK3845097 in Previously Treated Participants With Advanced Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

NCT05943990
View directory record Official record
Conditions
Neoplasms
Interventions
GSK3845097, Cyclophosphamide, Fludarabine
Drug
Lead sponsor
Adaptimmune
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
12
States / cities
New Haven, Connecticut • Jacksonville, Florida • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Sep 2, 2026, 3:54 PM EDT
Completed No phase listed Observational

Natural History Study for BEN

NCT00059423
View directory record Official record
Conditions
Neutropenia, Agranulocytosis, Hematologic Diseases, Leukocyte Disorders, Leukopenia
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
5 Years to 99 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Sep 2, 2026, 3:54 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab

NCT03709706
View directory record Official record
Conditions
Neoplasms
Interventions
Lete-cel, Pembrolizumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
20
States / cities
Duarte, California • La Jolla, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Sep 2, 2026, 3:54 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Collection and Distribution of Blood Components From Healthy Donors for In Vitro Research Use

NCT00001846
View directory record Official record
Conditions
Blood Donors, Research Subjects, Apheresis
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 100 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 2, 2026, 3:54 PM EDT
Terminated Phase 1 Interventional Results available

Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma

NCT03168438
View directory record Official record
Conditions
Neoplasms
Interventions
Letetresgene autoleucel, Letetresgene autoleucel with pembrolizumab, Fludarabine, Cyclophosphamide, Pembrolizumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
5
States / cities
Duarte, California • Miami, Florida • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Sep 2, 2026, 3:54 PM EDT
Recruiting No phase listed Observational

Apheresis of Patients With Immunodeficiency

NCT01212055
View directory record Official record
Conditions
LAD-1, DOCK8, GATA2 Deficancy
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 40 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 2, 2026, 3:54 PM EDT
Terminated Phase 1 Interventional

Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors

NCT01902771
View directory record Official record
Conditions
Glioma, Brain Cancer, Brain Tumor, Glioblastoma Multiforme, High Grade Glioma
Interventions
Dendritic Cell Vaccine, Tumor Lysate, Imiquimod, Leukapheresis
Biological · Other · Procedure
Lead sponsor
Edward Ziga
Other
Eligibility
1 Year to 29 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Sep 2, 2026, 3:54 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

LCI Apheresis to Obtain Plasma or White Blood Cells

NCT00562601
View directory record Official record
Conditions
Apheresis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
864 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1988 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 2, 2026, 3:54 PM EDT
Completed Phase 1 Interventional

Trial of Adoptive Immunotherapy With TRACT to Prevent Rejection in Living Donor Kidney Transplant Recipients

NCT02145325
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Expanded Tregs
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Sep 2, 2026, 3:54 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Evaluation of the Spectra Optia® Apheresis System Mononuclear Cell (MNC) Collection Procedure in Healthy Blood Donors

NCT01277549
View directory record Official record
Conditions
Leukapheresis
Interventions
Mononuclear cell collection.
Device
Lead sponsor
Terumo BCT
Industry
Eligibility
18 Years to 50 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
3
States / cities
Emeryville, California • Memphis, Tennessee • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 2, 2013 · Synced Sep 2, 2026, 3:54 PM EDT